造血器疾患に合併した重症感染症に対する Cefclidin の臨床効果と安全性の検討 阪神造血器疾患感染症研究グループ

巽 典之; 任 太性; 古川 佳央; 三宮 祐一; 井上 健; 陰山 克; 大藪 博; 赤坂 清司; 那須 芳; 米沢 毅; 烏野 隆博; 武 弘典; 杉山 治夫; 木谷 照夫; 田川 進一; 正岡 徹; 平岡 諦; 手島 博文; 安永 幸二郎; 藤竹 英樹; 吉岡 宗; 堀内 篤; 長谷川 廣文; 中山 志郎; 矢部 博樹; 川越 裕也; 平田 充彦; 永井 清保; 垣下 栄三; 武元 良整; 井上 信正

doi:10.11553/antibiotics1968b.45.512

THERAPEUTIC EFFECTS OF CEFCLIDIN AGAINST SEVERE INFECTIONS IN PATIENTS WITH HEMATOPOIETIC DISORDERS

Hanshin Infection Study Group

NORIYUKI TATSUMI, TAESUNG IM, YOSHIO FURUKAWA, YUICHI SANNOMIYA, KEN INOUE, TAKASHI KAGEYAMA, HIROSHI OHYABU, KIYOSHI AKASAKA, KAORI NASU, TAKESHI YONEZAWA, TAKAHIRO KARASUNO, HIRONORI TAKE, HARUO SUGIYAMA, TERUO KITANI, SHINICHI TAGAWA, TOHRU MASAOKA, AKIRA HIRAOKA, HIROBUMI TEJIMA, KOHJIRO YASUNAGA, HIDEKI FUJITAKE, MUNETO YOSHIOKA, ATSUSHI HORIUCHI, HIROFUMI HASEGAWA, SHIRO NAKAYAMA, HIROKI YABE, HIROYA KAWAGOE, MITSUHIKO HIRATA, KIYOYASU NAGAI, EIZO KAKISHITA, YOSHINOBU TAKEMOTO, NOBUMASA INOUE

Author information

NORIYUKI TATSUMI
Department of Laboratory Medicine, Osaka City University Medical School
TAESUNG IM
Department of Laboratory Medicine, Osaka City University Medical School
YOSHIO FURUKAWA
Department of Laboratory Medicine, Osaka City University Medical School
YUICHI SANNOMIYA
Department of Laboratory Medicine, Osaka City University Medical School
KEN INOUE
Department of Laboratory Medicine, Osaka City University Medical School
TAKASHI KAGEYAMA
The Second Department of Internal Medicine, Osaka Medical College
HIROSHI OHYABU
The Second Department of Internal Medicine, Osaka Medical College
KIYOSHI AKASAKA
Department of Internal Medicine, Osaka Red Cross Hospital
KAORI NASU
Department of Internal Medicine, Osaka Red Cross Hospital
TAKESHI YONEZAWA
The Second Department of Internal Medicine, Medical School, Osaka University
TAKAHIRO KARASUNO
The Second Department of Internal Medicine, Medical School, Osaka University
HIRONORI TAKE
The Second Department of Internal Medicine, Medical School, Osaka University
HARUO SUGIYAMA
The Third Department of Internal Medicine, Medical School, Osaka University
TERUO KITANI
Department of Internal Medicine, Research Institute for Microbial Diseases, Osaka University
SHINICHI TAGAWA
Department of Internal Medicine, Research Institute for Microbial Diseases, Osaka University
TOHRU MASAOKA
Department of Internal Medicine, The Center for Adult Diseases, Osaka
AKIRA HIRAOKA
Department of Internal Medicine, The Center for Adult Diseases, Osaka
HIROBUMI TEJIMA
Department of Internal Medicine, The Center for Adult Diseases, Osaka
KOHJIRO YASUNAGA
The First Department of Internal Medicine, Kansai Medical University
HIDEKI FUJITAKE
The First Department of Internal Medicine, Kansai Medical University
MUNETO YOSHIOKA
The First Department of Internal Medicine, Kansai Medical University
ATSUSHI HORIUCHI
The Third Department of Internal Medicine, School of Medicine, Kinki University
HIROFUMI HASEGAWA
The Third Department of Internal Medicine, School of Medicine, Kinki University
SHIRO NAKAYAMA
Department of Immunohematology, Kobe Central General Hospital
HIROKI YABE
Department of Immunohematology, Kobe Central General Hospital
HIROYA KAWAGOE
Department of Internal Medicine, Osaka National Hospital
MITSUHIKO HIRATA
Department of Internal Medicine, Osaka National Hospital
KIYOYASU NAGAI
The Second Department of Internal Medicine, Hyogo College of Medicine
EIZO KAKISHITA
The Second Department of Internal Medicine, Hyogo College of Medicine
YOSHINOBU TAKEMOTO
The Second Department of Internal Medicine, Hyogo College of Medicine
NOBUMASA INOUE
The Second Department of Internal Medicine, Hyogo College of Medicine

JOURNAL FREE ACCESS

1992 Volume 45 Issue 5 Pages 512-522

DOI https://doi.org/10.11553/antibiotics1968b.45.512

Details

Abstract

One hundred thirty-eight patients with severe infections associated with hematopoietic disorders were treated with cefclidin (CFCL), and the efficacy and the safety of the drug were evaluated.
The results obtained are summarized below.
1. Of the 126 patients in whom the efficacies were evaluable, 22 (17.5%) responsed markedly well and 48 (38.1%) moderately, and the overall efficacy rate was 55.6%.
2. Efficacy rates for different infections were: 20.0% in septicemia, 61.2% in suspected septicemia, 46.7% in respiratory tract infection and 25.0% in others.
3. Significantly different efficacy ratings were observed between a group of patients with neutrophil counts of less than 100/mm3 and that with neutrophil counts of higher than 501/mm3.
4. Out of 138 patients in whom the safety was evaluable, side effects were observed in 5 patients (3.6%) and abnormal laboratory test values in 9 (6.5%). None was serious, however.

Corresponding author

Register with J-STAGE for free!